CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Best ARK Stocks to Buy Right Now. On May 4, CRISPR Therapeutics AG (NASDAQ:CRSP) reported its first quarter 2026 results and advanced its pipeline and commercial launch. The company reported a net loss of $122.9 million for Q1 2026, lower than $136.0 million a year earlier. R&D expenses dipped to $68.6 million from $72.5 million, and G&A costs to $17.2 million from $19.3 million, the company said. Most importantly, its cash position actually strengthened, going up to $2.44 billion as of March 31, 2026, from $1.98 billion at the year’s end of 2025. The company reported that CRISPR Therapeutics AG (NASDAQ:CRSP)’s CASGEVY had $43 million in revenue, with more than 500 patients having treatment worldwide. Photo by National Cancer Institute on Unsplash CEO Samarth Kulkarni said the quarter showed “continued execution,” pointing out expanded Zugo Cel programs and continuous momentum for CASGEVY. He added that the corporation believes 2026 “will be a defining year,” noting multiple upcoming milestones. CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing firm that works on the development of Crispr/Cas9-based therapies. While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter 2026 results were decent as it beat estimates for earnings and sales. The company’s total revenues of $2.99 billion rose 8% year over year, driven by higher sales of cystic fibrosis (CF) drugs Trikafta/Kaftrio and Alyftrek, as well as meaningful contributions from new non-CF products, Journavx and Casgevy. Vertex reiterated its full-year 2026 revenue guidance in the range of $12.95-$13.10 billion for 2026. Investor focus was on the performance of Vertex’s newer drugs, Alyftrek, Journavx and Casgevy, which were launched in the past couple of years and hold the key to long-term growth. Alyftrek is a once-a-day oral triple combination regimen for CF. Journavx is a novel non-opioid pain medicine (suzetrigine) and Vertex and partner CRISPR Therapeutics’ CRSP Casgevy is a one-shot gene therapy approved for two blood disorders, sickle cell disease and transfusion-dependent beta-thalassemia. Year to date, shares of Vertex have declined 6.3% compared with the industry’s decrease of 0.2%. Image Source: Zacks Investment Research Let’s dig deeper to understand how these new products performed in the first quarter and the company’s outlook for the same through the rest of the year. Alyftrek continues to outperform expectations and generated sales worth $424.4 million in the first quarter compared with $380.1 million in the fourth quarter. The rollout of Alyftrek in the United States and Europe is progressing well across all patient groups. The drug has now surpassed $1 billion in cumulative global revenues since its approval in the United States in late 2024 and in the EU in July 2025. Alyftrek’s once-daily dosing and improved sweat chloride profile continue to resonate with patients and doctors. In the first quarter, products from Vertex’s new non-CF disease areas, namely Casgevy and Journavx, drove approximately 25% of total product revenue growth, which was encouraging as Vertex’s dependence on just the CF franchise for revenues has been a growing concern. CF sales are also slightly slowing down. Journavx (suzetrigine) generated $29 million in sales in the first quarter compared with $26.7 million in the fourth quarter. Prescription growth remains strong, although first-quarter revenues reflected some normal inventory destocking. More than 350,000 prescriptions were written for Journavx across both hospital and...

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.47 per share for the first quarter of 2026, beating the Zacks Consensus Estimate of $4.23. Earnings rose around 10.1% year over year on higher product revenues. First-quarter total revenues of $2.99 billion slightly beat the Zacks Consensus Estimate of $2.98 billion. Total revenues rose 8% year over year, primarily driven by higher sales of cystic fibrosis (CF) drugs Trikafta/Kaftrio and Alyftrek, as well as meaningful contributions from other new products, Journavx and Casgevy. Year to date, shares of Vertex have declined 5.2% compared with the industry’s decrease of 3.2%. Image Source: Zacks Investment Research Trikafta generated sales worth $2.35 billion, down 7.5% year over year. The product’s sales missed the Zacks Consensus Estimate of $2.39 billion. Alyftrek, a next-in-class triple combination regimen for CF, generated sales worth $424.4 million in the first quarter compared with $380.1 million in the fourth quarter. Per management, the U.S. and European launch of Alyftrek is progressing well across all patient groups. The drug has now surpassed $1 billion in cumulative global revenue since its approval. Revenues from other CF products decreased 12.5% year over year to $135.9 million. Revenues from Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy, Casgevy, were $42.9 million in the first quarter of 2026, down from $54.3 million recorded in the fourth quarter of 2025. Casgevy is approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement, with support from CRISPR Therapeutics. Vertex’s newest pain drug, Journavx (suzetrigine) generated $29 million in sales in the first quarter compared with $26.7 million in the fourth quarter. Journavx, a novel non-opioid pain medicine (suzetrigine), was approved in the United States in January 2025. Adjusted research and development (R&D) expenses declined 2.2% year over year to $859.3 million. Adjusted selling, general and administrative (SG&A) expenses rose 29.8% to $432.2 million in the reported quarter, primarily to support the launch of Journavx. During the quarter, Vertex recorded acquired in-process research and development (AIPR&D) costs of $0.5 million compared with $19.8 milli...

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflected continued execution across CRISPR Therapeutics’ platform,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “We expanded zugo-cel into new autoimmune indications and advanced multiple in vivo liver-directed programs toward the clinic, while CASGEVY continued its momentum. With a strengthened balance sheet and multiple upcoming milestones, we believe 2026 will be a defining year for CRISPR Therapeutics." Recent Highlights and Outlook Hemoglobinopathies and CASGEVY® (exagamglogene autotemcel) CASGEVY is approved in the U.S., Canada, the U.K., the EU, Switzerland, the Kingdom of Saudi Arabia (KSA), the Kingdom of Bahrain, Qatar, the United Arab Emirates (UAE), and Kuwait for patients 12 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). In total, there are more than 60,000 eligible patients in these countries, including approximately 37,000 in North America and Europe and more than 23,000 in the Middle East. CASGEVY generated first quarter 2026 revenue of $43 million. More than 500 people globally have now initiated the CASGEVY treatment journey, reflecting continued commercial momentum. Vertex has completed the U.S. regulatory submission for approval of CASGEVY in children ages 5 to 11 years old with SCD or TDT, extending the potential treatment population to a younger age group. The U.S. Food and Drug Administration (FDA) awarded a Commissioner's National Priority Voucher for this pediatric submission, supporting an accelerated review timeline once accepted. Access to CASGEVY continued to expand across key markets. Most recently, a pricing agreement was secured for eligible patients with SCD or TDT in Germany, with final implementation underway. As of year-end 2025, approximately 90% of patients in the U.S. had reimbursed access to CASGEVY, which is also reimbursed in the U.K., Italy, Austria, Denmark, Luxembourg, KSA, the Kingdom of Bahrain, the UAE, and Kuwait. CRISPR Therapeutics continues to advance its in vivo hematopoietic stem cell editing approach using lipid nanoparticle (LNP)-mediated delivery. This approach has the potential to expand the addressable patien...

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for Casgevy, the gene therapy it co-commercializes with Vertex Pharmaceuticals. An interesting angle for investors is how Casgevy’s early commercial uptake and growing treated-patient base may influence perceptions of CRISPR Therapeutics’ broader gene-editing platform and revenue potential. With the stock experiencing a 10.10% seven-day decline, we’ll examine how Casgevy’s commercialization prospects shape CRISPR Therapeutics’ investment narrative. Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution. To own CRISPR Therapeutics, you have to believe its gene‑editing science can translate into durable commercial products, starting with Casgevy and extending into its in vivo and oncology pipeline. The latest expectations for higher March‑quarter earnings and revenue, helped by strong Casgevy launch metrics at Vertex, feed directly into that story by suggesting early real‑world traction for its first approved therapy. In the near term, Casgevy uptake and any updated revenue sharing detail with Vertex look like the key catalysts, alongside readouts from programs like CTX310 and zugo‑cel that could broaden the platform’s relevance. At the same time, the company is still generating minimal revenue against large losses, so the recent 10% weekly pullback suggests the market is willing to reassess risk quickly if execution wobbles. However, one risk stands out that investors may be underestimating right now. Despite retreating, CRISPR Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much. The Simply Wall St Community’s 10 fair value views for CRISPR Therapeutics stretch from about US$31 to above US$185, underscoring how far apart expectations can be. Set those against the reliance on Casgevy’s early commercialization and a still loss‑making profile, and you can see why it pays to compare several viewpoints before forming your own stance. Explore 10 other fair value estimates on CRISPR Therapeutics - why the stock might be worth 39% less than the current price! Don't just follow the ticker - dig into the data and build a conviction th...

Vertex Pharmaceuticals VRTX is scheduled to report its first-quarter 2026 results on May 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.98 billion, while the same for earnings is $4.20 per share. Let’s see how things might have shaped up before the announcement. Vertex’s revenues in the to-be-reported quarter are likely to have been driven by strong demand for blockbuster cystic fibrosis (“CF”) medicine, Trikafta/Kaftrio (Trikafta’s brand name in Europe), in the United States. The Zacks Consensus Estimate for Trikafta/Kaftrio sales is currently pegged at $2.40 billion. However, higher Trikafta/Kaftrio sales are likely to have caused sales erosion of VRTX’s other CF drugs — Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. Though Vertex’s CF franchise sales continue to grow, driven by demand growth of Trikafta/Kaftrio in younger age groups, we expect investors to focus on the sales performance of its fifth CF medicine, Alyftrek (vanza triple), during the first quarter. Alyftrek sales increased sequentially in the last reported quarter, a trend most likely to have continued in the to-be-reported quarter. Per management, the U.S. launch of Alyftrek is progressing well across all patient groups, while in ex-U.S. markets, the early launch of Alyftrek is off to a strong start in multiple European countries, where patients have reimbursed access. Year to date, shares of Vertex have plunged 6.1% compared with the industry’s decline of 1.2%. Image Source: Zacks Investment Research Vertex and its partner CRISPR Therapeutics’ CRSP one-shot gene therapy, Casgevy, was approved in late 2023/early 2024 for two blood disorders — sickle cell disease and transfusion-dependent beta-thalassemia. Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement, with support from CRISPR Therapeutics. Casgevy sales increased significantly on a sequential basis in the last quarter due to robust patient growth. Vertex is also making rapid progress in the drug’s access and reimbursement. In 2026, Vertex expects significant growth in Casgevy’s sales as the therapy’s launch metrics look positive, with growing cell collections and product infusions. Investors will be keen to get more updates on the same on the upcoming earnings call. VRTX’s novel non-opioid pain medicine...

Mirum Pharmaceuticals, Inc. (MIRM) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This company is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of -36.7%. Revenues are expected to be $149.1 million, up 33.6% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 2.84% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A p...

The market expects CRISPR Therapeutics AG (CRSP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This company is expected to post quarterly loss of $1.14 per share in its upcoming report, which represents a year-over-year change of +27.9%. Revenues are expected to be $8.39 million, up 864.4% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.42% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP...

We expect CRISPR Therapeutics CRSP to surpass expectations when it reports first-quarter 2026 results. The company’s earnings missed estimates by 19.13% in the last reported quarter. The Zacks Consensus Estimate for quarterly sales is pegged at $8.39 million, while that for earnings is pinned at a loss of $1.14 per share. Both metrics indicate improvement over the year-ago period. CRISPR Therapeutics’ top line currently includes grants and collaboration revenues from its partnership with pharma giant Vertex Pharmaceuticals VRTX. The company and Vertex’s one-shot gene therapy, Casgevy, is approved for two blood disorders, namely sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), across the United States and Europe. This therapy is the first and currently the only marketed product in CRISPR Therapeutics’ portfolio. Per the collaboration agreement, VRTX leads global development, manufacturing and commercialization, and splits program costs and profits in a 60:40 ratio with the company. CRSP records its share of Casgevy sales as an adjustment to collaboration expenses (net) rather than as direct revenues. Sales of the gene therapy have been rising in recent quarters, likely leading to lower collaboration expenses in the to-be-reported quarter. Investors are likely to have looked for updates on the global regulatory submissions, planned for the first half of 2026, seeking label expansion for Casgevy in patients aged 5-11 years with SCD and TDT. For the FDA submission, Vertex intends to use the Commissioner’s National Priority Voucher to significantly cut down the review period to just 1-2 months. Following the success of Casgevy, which is an ex vivo therapy, the company has shifted focus toward in vivo candidates. CRISPR Therapeutics is currently evaluating its first in vivo candidate CTX310 — designed to target ANGPTL3 for cardiovascular disease — in an early-stage clinical study. It plans to expand this pipeline with additional candidates, including CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency (AATD). Investors are likely to have been watching for updates on study initiation timelines, which management previously indicated could begin by the end of this year. The biotech firm’s performance has been mixed over the past four quarters. Its earnings beat estimates in two of the trailing four quarters and...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. The FDA's draft guidance to speed approval of genome editing and RNA therapies has put CRISPR Therapeutics (CRSP) in focus, even as the company recently reported soft fourth quarter and full year 2025 results. See our latest analysis for CRISPR Therapeutics. Over the past year, CRISPR Therapeutics has combined weak reported earnings with a regulatory backdrop that some investors may see as supportive, with a 1 year total shareholder return of 24.32%, a 3.56% 90 day share price return, and a 2.66% year to date share price gain from the latest close of US$55.20. However, the 5 year total shareholder return of a 53.64% decline highlights how sentiment has shifted over a longer horizon. If the mix of regulation and earnings at CRISPR Therapeutics has your attention, it could be a good moment to broaden your watchlist with 30 healthcare AI stocks as potential ideas to research next. With the stock at US$55.20 and trading at a large discount to one commonly cited price target and intrinsic estimates, you have to ask: is CRISPR Therapeutics undervalued here, or is the market already pricing in future growth? At a last close of $55.20, CRISPR Therapeutics is screening as mixed value, with a P/B ratio of 2.8x that looks cheap versus peers but slightly rich versus the broader US Biotechs industry. P/B compares the market value of a company to its net assets on the balance sheet and is often used when profits are not yet in place or are volatile. This fits CRISPR Therapeutics given its current loss of $581.599m and lack of meaningful revenue of about $4m. Relative to similar companies, the 2.8x P/B is described as good value against a peer average of 15.5x. This suggests the market is assigning a lower book value multiple to CRISPR Therapeutics than to many companies in its closer comparison group. However, against the wider US Biotechs industry, that same 2.8x P/B is described as expensive compared to the 2.7x industry average. Investors weighing this metric have to decide whether to focus on the broader industry comparison or the much higher peer average. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 2.8x (ABOUT RIGHT) However, the large net loss of US$581.599m and limited revenue base of US$3.51m, tog...

CRISPR Therapeutics’ Q4 reaction reflects longer-term optimism despite weak reported revenue tied to launch economics. CASGEVY adoption is a key narrative driver, but profitability hinges on timing, revenue-sharing mechanics, and pipeline progress. With substantial cash on hand, the near-term question is technical/entry risk, while the long-term question is execution. Interested in CRISPR Therapeutics AG? Here are five stocks we like better. CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory. The company posted a larger net loss than forecast, and revenue came in at a fraction of expectations. → Corning’s Surprise AI Boom: Is It Already Too Late to Buy? But CRISPR is a long-term story that is still in the early innings. The company has moved past its proof-of-concept phase, but investors will have to be patient. The payoff as the company moves into a mature growth phase is likely a year or two away. In December 2023, CRISPR received U.S. Food & Drug Administration (FDA) approval for CASGEVY. This was the company’s flagship gene therapy for sickle cell disease and beta thalassemia. It was the first CRISPR/Cas9 gene-editing technology to be approved by the FDA. → 3 Discount Retail Stocks to Watch as Earnings Put Valuations to the Test CRSP stock, however, is down approximately 19% since that announcement. Some of that has to do with growth already being priced in. However, some of it has to do with the nature of CRISPR’s partnership with Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). The partnership was critical to getting CASGEVY approved. But it also comes with a revenue split arrangement whereby CRISPR only recognizes revenue after Vertex has recouped a certain share of its launch and manufacturing costs. So while CASGEVY generated $54 million in the most recent quarter, CRISPR reported quarterly revenue of just $0.86 million. → Ondas Jumps on German Police and NATO Wins—Can the Rally Hold Into Earnings? This helps frame the investment thesis for CRSP stock. On the one hand, there is an increase in patients receiving CASGEVY. On the other hand, the company is reporting larger losses from operations as it works to bring additional pipeline candidates to market. The key number may be the company’s cash and investment balance of aroun...

By all accounts its stock should be in the red today. CRISPR Therapeutics (NASDAQ: CRSP) only reported $864,000 in fourth-quarter revenue after Thursday's closing bell, leading to a loss of $1.37 per share versus analysts' estimates for a loss of only around $1.20 per share on sales of at least a few million dollars. Yet, as of 2:03 p.m. ET Friday, CRISPR shares are higher to the tune of 9.7%. What gives? Thank Vertex Pharmaceuticals (NASDAQ: VRTX), mostly. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » CRISPR Therapeutics' gene-editing therapy Casgevy is impressive enough in its own right, by virtue of being the FDA' first-ever approved gene-editing therapy (for the treatment of sickle cell disease). CRISPR Therapeutics still faces the same struggles most other young biotechnology companies do, however. Chief among these challenges is lingering -- and often significant -- losses and inconsistent, unpredictable revenue. Many biotech start-ups need a bigger developmental partner to help a new treatment reach its full commercialization potential. For CRISPR, that partner is licensee Vertex Pharmaceuticals, which coincidentally also reported its fourth-quarter results on Thursday evening. Although it only recorded $54 million worth of Casgevy revenue during the three months ending in December, Vertex added that it anticipates "$500 million or more in revenue from non-CF [cystic fibrosis] products, including increased patient infusions of Casgevy through Vertex's global ATC [authorized treatment centers] network" in 2026. While Vertex's outlook doesn't clarify exactly how much revenue CRISPR Therapeutics can expect to book for itself in the year ahead nor when it will be booking it, it does confirm that the company's commercialization partner sees growth well beyond Casgevy's 2025 total revenue of $116 million. Vertex's bold 2026 guidance for Casgevy's sales growth shouldn't actually be all that surprising. Although it was first approved in late-2023, it can take months to prepare treatment centers, and then requires several more months to create each patient-specific treatment. Neither CRISPR Therapeutics nor Vertex Pharmaceuticals ever expected this therapy to produce massive revenue right out of the gate, particularly given its cost of ov...